Pulmonary arterial hypertension (PAH) is characterized by remodeling of the extracellular
matrix (ECM) of the pulmonary arteries with increased collagen deposition, cross-linkage of …

Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease
characterized by increased pulmonary vascular resistance (PVR) leading to right ventricular …

The diagnosis and management of pulmonary arterial hypertension (PAH) includes several
advances, such as a broader recognition of extrapulmonary vascular organ system …

Pregnancy outcomes in patients with pulmonary hypertension remain poor despite
advanced therapies. Although consensus guidelines recommend against pregnancy in …

Background: Patients with protein-losing enteropathy (PLE) following the Fontan operation
have a reported 50% mortality at 5 years after diagnosis. Objectives: The aim of this study …

Pulmonary hypertension is a complex disease with multiple causes, corresponding to
phenotypic heterogeneity and variable therapeutic responses. Advancing understanding of …

Advanced phenotyping of cardiovascular diseases has evolved with the application of high-
resolution omics screening to populations enrolled in large-scale observational and clinical …

Germline mutations involving small mothers against decapentaplegic–transforming growth
factor–β (SMAD–TGF-β) signaling are an important but rare cause of pulmonary arterial …

Pulmonary arterial hypertension (PAH) is due to progressive distal pulmonary artery (PA)
obstruction, leading to right ventricular hypertrophy and failure. Exacerbated store-operated …

Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right
ventricular dysfunction and exercise limitation and progresses to death. New findings from …